These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2490816)

  • 1. Angiotensin converting enzyme inhibitors. Present and future.
    Frohlich ED
    Hypertension; 1989 May; 13(5 Suppl):I125-30. PubMed ID: 2490816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Angiotensin-converting enzyme inhibition: direct and indirect mechanisms].
    Stumpe KO
    Klin Wochenschr; 1985 Sep; 63(18):897-906. PubMed ID: 2997540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular hypertrophy: dissociation of structural and functional effects by therapy.
    Frohlich ED
    Adv Exp Med Biol; 1991; 308():175-90. PubMed ID: 1839347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertensive mechanisms and converting enzyme inhibitors.
    Ferrario CM; Jaiswal N; Yamamoto K; Diz DI; Schiavone MT
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV56-62; discussion IV83-90. PubMed ID: 1893643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of ACE inhibitors in heart failure (mechanism of action)].
    Drexler H
    Z Kardiol; 1992; 81 Suppl 4():85-91. PubMed ID: 1290308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of blood pressure by the renin-angiotensin-aldosterone system.
    Hall JE
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV6-21; discussion IV51-5. PubMed ID: 1893644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin-angiotensin system in left ventricular remodeling.
    Blaufarb IS; Sonnenblick EH
    Am J Cardiol; 1996 May; 77(13):8C-16C. PubMed ID: 8638527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.